Cole Bryant: Hey — okay, real talk, I almost cancelled today because I wanted to spend more time with this story, that's how deep in it I am.
Zara Reyes: You mean the Lucy Ackman thing. Yeah, I figured that's where we were going.
Cole Bryant: Dude, mitochondria. From a leg. Into eyes. That's — wait, can I just start with what actually happened because I don't think people grasp how wild the timeline is?
Cole Bryant: February 2026. Lucy Ackman, she's twenty-six, she collapses in her Brooklyn apartment. Catastrophic brain hemorrhage. And the doctors at Mount Sinai are essentially saying — no movement, no speech, no vision. That's the prognosis.
Zara Reyes: Her father is Bill Ackman. Hedge fund manager, billionaire — and that fact is doing a LOT of work in this story before we even get to the science.
Cole Bryant: No, totally — but the science, okay: by May, David Putrino and Christopher Kellner are injecting mitochondria from her own leg muscle into both of her eyes. No one had ever done this to human eyes. Not once.
Zara Reyes: It worked for four weeks. Shapes, shadows. Then gone. That's the tease and I cannot stop thinking about it.
Cole Bryant: Wait but — okay, four weeks, then gone, but can we back up for a second? Because I don't think I actually understand what they physically did. Like, mitochondria from a leg. Into eyes. What does that even mean on a mechanical level?
Zara Reyes: Okay, forget the medical language. Your mitochondria are your cells' batteries. That's it. They pulled the batteries out of healthy leg muscle — tissue that doesn't need them as urgently — and plugged them into her dying eye cells to try to get the lights back on.
Cole Bryant: The lights back on. That's — yeah, okay that actually landed.
Zara Reyes: And the thing that nobody's really clocking is that this procedure has existed since 2017. First mitochondrial transplant between body parts — abdominal muscle to the heart. Dozens of heart transplants since then. A brain transplant in 2024. But eyes? Nobody touched eyes. Not once.
Cole Bryant: Dude, why though? Like why are eyes last? What's different about the optic nerve that everyone just — skipped it?
Zara Reyes: Honestly? I don't fully know and I don't think the research spells it out cleanly. My read — and I'm hedging here — is that the optic nerve is just a different animal. It's central nervous system tissue, it doesn't regenerate the same way heart muscle does, so maybe the assumption was that the mitochondria wouldn't hold. But that's me filling in a gap, not quoting a study.
Cole Bryant: No but that actually makes the FDA piece more insane to me — like, they had no roadmap for this specific case, right? This wasn't an approved protocol. The FDA had to grant emergency expanded access, compassionate use, and apparently that authorization itself was a first. For mitochondrial eye transplantation specifically.
Zara Reyes: That's the thing that made it possible at all. Compassionate use is the FDA pathway for — basically, serious or life-threatening condition, no comparable alternative exists, and you get access outside of any clinical trial. The fact that they described this authorization as a first-of-its-kind for this procedure means Mount Sinai and David Putrino and Christopher Kellner were writing the permission structure in real time.
Cole Bryant: Writing the permission structure in real time while a twenty-six-year-old can't see. Bro. That timeline is not normal.
Zara Reyes: And that timeline that isn't normal is exactly where the headline breaks. Because the headline is already 'Billionaire's daughter gets vision back through experimental surgery' — and that's wrong on like two separate levels.
Cole Bryant: Wait, wrong how? Because the pupils reacted to light. She perceived shapes and shadows through her left eye. That's real, right?
Zara Reyes: It's real — no inflammation, no rejection, pupils responding. I'm not disputing that. But 'gets vision back' implies she has vision. She had four weeks of partial signal in one eye and then it faded. That's not a restoration, that's a — I mean, it's a flicker. A very significant flicker, but.
Cole Bryant: Okay but here's what trips me up — the case is in a preprint. August 10, 2026. Not peer reviewed. So the Washington Post story from September ran before the actual science has been vetted by anyone?
Zara Reyes: The Washington Post is currently carrying more institutional weight than the paper itself. That is the situation we are in.
Cole Bryant: Bro. That's — that's actually kind of insane when you say it out loud.
Zara Reyes: And the other thing — optic nerve damage from a brain hemorrhage is not the pathology affecting millions of people losing vision. The retinal degeneration cases, the limbal stem cell conditions — those are the dominant vision-loss populations. So even if the preprint gets reviewed and holds up, the generalizability is, like, genuinely narrow. One patient, no control, atypical cause.
Cole Bryant: No but — okay wait, that's actually the part that should scare people about the framing. Because if you can't generalize it, and the result didn't sustain, and it's unreviewed — what are we actually celebrating? Like, what is the claim?
Zara Reyes: Proof of concept, maybe. Tentatively. And honestly — the part we haven't even gotten to yet is who gets to be first in line for the next tentative proof of concept, and why. That's where this whole story gets a different kind of uncomfortable.
Cole Bryant: And that's the part — like, who gets to access the next tentative proof of concept is just... it's February to May. That's four months. That is not how experimental medicine moves for a regular twenty-six-year-old without a billionaire father making calls.
Zara Reyes: The Washington Post literally called him a 'daring father.' That framing is doing so much. His agency is centered. His bet is the headline.
Cole Bryant: Which — okay, I get why they wrote it that way, but dude. The FDA emergency expanded access pathway exists for everyone theoretically. The reality is you need institutional will behind you to actually move it in four months. That's lawyers, that's connections, that's Mount Sinai picking up the phone because Bill Ackman is calling.
Zara Reyes: A different family in a different waiting room — same hemorrhage, same age — that authorization is not happening in four months. Probably not happening at all.
Cole Bryant: Right? And so — wait, no, here's what I actually can't land on. If this preprint eventually gets peer-reviewed and holds up and it seeds a proper clinical trial — is the story then that Lucy opened this door for everybody? Or is it that money bought the front of the line and we all just... benefited from that?
Zara Reyes: Both. Uncomfortably both.
Cole Bryant: Yeah. That's — I hate that that's the answer but it's the answer.
Zara Reyes: And the thing to actually watch is whether the preprint — August 10, still sitting unreviewed — whether that no-inflammation, no-rejection signal is enough to attract formal trial funding. Because that safety data, even from one patient, is what extends mitochondrial transplantation to a third organ system. That's real. That matters to researchers. But it only matters if the coverage doesn't create such inflated expectations that the funding chases a cure story instead of a mechanism question.
Cole Bryant: So the Washington Post story could either accelerate the science or completely poison the well for what the science actually needs to answer.
Zara Reyes: The preprint is from August 10th, sitting unreviewed, and we still don't know why it stopped. Four weeks. Nobody knows what ended it. That's not a footnote, that's the whole next question.
Cole Bryant: Mine is that her pupils started reacting to light. Like — after all of that, after February, after the hemorrhage, after total darkness — her pupils moved. That's the detail that sticks with me.
Zara Reyes: And if the system that moved in four months for Lucy has any mechanism to move that fast for someone without Bill Ackman's phone number — I mean, I genuinely don't know. I don't think anyone does yet.
Cole Bryant: Yeah. No answer on that. But — okay, I'm toasting Lucy's pupils reacting to light. That happened. That was real.
Zara Reyes: Genuinely. To the flicker. Alright — go home.
